Confounders and co-interventions identified in non-randomized studies of interventions.

Acute coronary syndrome (ACS) Bleeding Clinical practice research datalink (CPRD) Confounders Coronary artery bypass grafting (CABG) Dual antiplatelet therapy (DAPT) Hospital episode statistics (HES) Non-randomized studies of interventions (NRSI) Percutaneous coronary intervention (PCI) Target trial

Journal

Journal of clinical epidemiology
ISSN: 1878-5921
Titre abrégé: J Clin Epidemiol
Pays: United States
ID NLM: 8801383

Informations de publication

Date de publication:
08 2022
Historique:
received: 16 10 2021
revised: 14 02 2022
accepted: 23 03 2022
pubmed: 30 3 2022
medline: 27 10 2022
entrez: 29 3 2022
Statut: ppublish

Résumé

To identify potential confounders and co-interventions systematically to optimise control of confounding for three non-randomized studies of interventions (NRSI) designed to quantify bleeding in populations exposed to different dual antiplatelet therapy (DAPT). Systematic review, interviews, and surveys with clinicians. We searched Ovid Medline, Ovid Embase, and the Cochrane Library to identify randomized-controlled trials and cohort studies of DAPT interventions. Two researchers independently screened citations, identified eligible studies and extracted data. We conducted individual semi-structured interviews with six cardiologists and six cardiac surgeons to elicit factors clinicians consider when they prescribe DAPT. We administered two online surveys for members of professional cardiology and cardiac surgery organisations. We screened 2,544 records, identified 322 eligible studies, and extracted data from 47. We identified 10 co-interventions and 70 potential confounders: review 31 (91%); interviews 19 (56%); surveys 31 (91%). 16/34 (47%) were identified by all three methods while, 3/34 (9%) were picked up by one method only. The review identified the majority of factors, but the interviews identified hard-to-measure factors such as perceived patient adherence and local prescribing culture. The methods could, in principle, be widely applied when designing or reviewing non-randomized studies of interventions (NRSI).

Identifiants

pubmed: 35346782
pii: S0895-4356(22)00079-8
doi: 10.1016/j.jclinepi.2022.03.018
pii:
doi:

Substances chimiques

Platelet Aggregation Inhibitors 0

Types de publication

Systematic Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115-123

Subventions

Organisme : Medical Research Council
ID : MR/M025209/1
Pays : United Kingdom
Organisme : British Heart Foundation
Pays : United Kingdom

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Auteurs

Maria Pufulete (M)

Bristol Trials Centre (Clinical Trials and Evaluation Unit), Bristol Medical School, University of Bristol, Bristol, UK; NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, Bristol, UK. Electronic address: maria.pufulete@bristol.ac.uk.

Kalaivani Mahadevan (K)

Bristol Heart Institute, Bristol, UK.

Thomas W Johnson (TW)

Bristol Heart Institute, Bristol, UK.

Christalla Pithara (C)

The National Institute for Health Research Applied Research Collaboration West (NIHR ARC West) at University Hospitals Bristol and Weston NHS Foundation Trust, UK.

Sabi Redwood (S)

The National Institute for Health Research Applied Research Collaboration West (NIHR ARC West) at University Hospitals Bristol and Weston NHS Foundation Trust, UK.

Umberto Benedetto (U)

Bristol Heart Institute, Bristol, UK.

Julian P T Higgins (JPT)

NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, Bristol, UK; The National Institute for Health Research Applied Research Collaboration West (NIHR ARC West) at University Hospitals Bristol and Weston NHS Foundation Trust, UK; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Barnaby C Reeves (BC)

Bristol Trials Centre (Clinical Trials and Evaluation Unit), Bristol Medical School, University of Bristol, Bristol, UK; NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH